Hai T. Tran

15.0k citations

168 papers · 7.5k indexed · 1 hit paper · h-index 42

Oncology top 0.5%
Molecular Biology top 2%
Pulmonary and Respiratory Medicine top 0.5%
Cancer Research top 1%
Hematology top 1%

Co-authors: John V. Heymach Roy S. Herbst Alan Sandler David H. Johnson David A. Ramies Bruce E. Johnson Timothy Madden Pam Klein
Topics: Lung Cancer Treatments and Mutations (45 papers)Cancer Genomics and Diagnostics (22 papers)Lung Cancer Research Studies (19 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Nature Medicine
Partner nations: United States Vietnam China

In The Last Decade

Hai T. Tran

163 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 1.2k citations Roy S. Herbst, Bruce E. Johnson et al. profile →

Peers

Countries citing papers authored by Hai T. Tran

Since Specialization

Citations

This map shows the geographic impact of Hai T. Tran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hai T. Tran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hai T. Tran more than expected).

Fields of papers citing papers by Hai T. Tran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hai T. Tran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hai T. Tran. The network helps show where Hai T. Tran may publish in the future.

Co-authorship network of co-authors of Hai T. Tran

This figure shows the co-authorship network connecting the top 25 collaborators of Hai T. Tran. A scholar is included among the top collaborators of Hai T. Tran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hai T. Tran. Hai T. Tran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations 2025 ·ESMO Open ·Sarina A. Piha‐Paul,Chieh Tseng,Hai T. Tran,Aung Naing,Ecaterina E. Dumbrava,(unknown),Jordi Rodón,Timothy A. Yap,Kanwal Raghav,Senthil Damodaran,Xiao‐Feng Le,(unknown),(unknown),(unknown)	2
2	995MO Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade 2024 ·Annals of Oncology ·Adam Grippin,(unknown),(unknown),Erin L. Young,(unknown),Ellen T. Chang,Ramez Kouzy,Jeff Lewis,Xiaolin Wei,(unknown),Jih‐Jong Lee,(unknown),(unknown),Hai T. Tran,(unknown),John V. Heymach,J. Zhang,Elias Sayour,Wen Jiang,Steven H. Lin	2
3	Alpha-glucosidase inhibitory compounds from Vietnamese lichen Usnea baileyi: in vitro and in silico aspects 2024 ·RSC Advances ·(unknown),Thuc‐Huy Duong,(unknown),Hai T. Tran,(unknown),Jirapast Sichaem,(unknown),Huy Truong Nguyen,(unknown)	2
4	High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC 2024 ·Journal for ImmunoTherapy of Cancer ·Mehmet Altan,(unknown),Ziyi Li,Runzhe Chen,Ajay Sheshadri,Hai T. Tran,Latasha Little,(unknown),(unknown),Natalie I. Vokes,Saumil Gandhi,Mara B. Antonoff,Stephen G. Swisher,Gregory Lizée,Alexandre Reuben,John V. Heymach,Jianjun Zhang	5
5	Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer 2023 ·Annals of Oncology ·Hai T. Tran,Simon Heeke,Sheeba J. Sujit,Natalie I. Vokes,J. Zhang,Muhammad Aminu,Vincent K. Lam,Ara A. Vaporciyan,Stephen G. Swisher,Myrna C.B. Godoy,Tina Cascone,Boris Sepesi,Don L. Gibbons,Jia Wu,John V. Heymach	32
6	IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC 2023 ·Clinical Cancer Research ·Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach	62
7	Image Based Visual Servo Control with a Two-Axis Inertially Stabilized Platform Using Deep Deterministic Policy Gradient 2022 ·Tien Pham,(unknown),(unknown),Hai T. Tran	1
8	Plasma Based Protein Signatures Associated with Small Cell Lung Cancer 2021 ·Cancers ·Johannes F. Fahrmann,Hiroyuki Katayama,Ehsan Irajizad,(unknown),(unknown),Xiangying Mao,(unknown),Eunice Murage,(unknown),(unknown),(unknown),(unknown),Jennifer B. Dennison,Hai T. Tran,Edwin J. Ostrin,David O. Wilson,Jian‐Min Yuan,(unknown),Samir Hanash	6
9	P1.01-98 Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing 2019 ·Journal of Thoracic Oncology ·Hai T. Tran,Vincent K. Lam,(unknown),Lingzhi Hong,Rivka R. Colen,Nabil Elshafeey,Islam Hassan,Vassiliki A. Papadimitrakopoulou,George R. Blumenschein,(unknown),George R. Simon,Richard B. Lanman,Victoria M. Raymond,Yasir Y. Elamin,Mehmet Altan,Anne S. Tsao,Don L. Gibbons,J. Zhang,John V. Heymach	1
10	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib 2015 ·Clinical Cancer Research ·Monique B. Nilsson,Uma Giri,Jayanthi Gudikote,Ximing Tang,Wei Lü,Hai T. Tran,You-Hong Fan,Andrew B. Koo,Lixia Diao,Pan Tong,Jing Wang,Roy S. Herbst,Bruce E. Johnson,Andy Ryan,Alan Webster,Philip Rowe,Ignacio I. Wistuba,John V. Heymach	10
11	Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial 2013 ·Journal of Thoracic Oncology ·Anne S. Tsao,Suyu Liu,J. Jack Lee,Christine Alden,George R. Blumenschein,Roy S. Herbst,Suzanne E. Davis,Edward Kim,Scott M. Lippman,John V. Heymach,Hai T. Tran,Ximing Tang,Ignacio I. Wistuba,Waun Ki Hong	19
12	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept 2011 ·Clinical Cancer Research ·John de Groot,Yuji Piao,Hai T. Tran,Mark R. Gilbert,(unknown),Jun Liu,B. Nebiyou Bekele,Tim Cloughesy,Minesh P. Mehta,H. Ian Robins,Andrew B. Lassman,Lisa M. DeAngelis,Kevin Camphausen,Alice P. Chen,W.K. Alfred Yung,Michael D. Prados,Patrick Y. Wen,John V. Heymach	51
13	Effect of Low-Fat Diets on Plasma Levels of NF-κB–Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer 2011 ·Cancer Prevention Research ·John V. Heymach,Terry J. Shackleford,Hai T. Tran,Suk-Young Yoo,Kim‐Anh Do,Melanie Wergin,Pierre Saintigny,Robin T. Vollmer,Thomas J. Polascik,Denise C. Snyder,Mack T. Ruffin,Shaoyu Yan,Mark W. Dewhirst,Ajaikumar B. Kunnumakkara,Bharat B. Aggarwal,Wendy Demark‐Wahnefried	43
14	Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells 2009 ·Molecular Cancer Therapeutics ·Ralph Zinner,(unknown),Elmira Popova,Paul Damien,Andrei Y. Volgin,Juri G. Gelovani,Reuben Lotan,Hai T. Tran,Claudio Pisano,Gordon B. Mills,(unknown),Waun Ki Hong,Scott M. Lippman,John H. Miller	48
15	High-Dose Fenretinide in Oral Leukoplakia 2009 ·Cancer Prevention Research ·William N. William,J. Jack Lee,Scott M. Lippman,Jack W. Martin,Nitin Chakravarti,Hai T. Tran,Anita L. Sabichi,Edward S. Kim,Lei Feng,Reuben Lotan,Vassiliki A. Papadimitrakopoulou	33
16	A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer 2009 ·Cancer ·Edward S. Kim,Ann M. Mauer,William N. William,Hai T. Tran,Diane Liu,J. Jack Lee,(unknown),Waun Ki Hong,Everett E. Vokes,Roy S. Herbst	27
17	Cyclic AMP-Responsive Element Binding Protein– and Nuclear Factor-κB–Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis 2008 ·Cancer Prevention Research ·Hongxia Sun,Wen-Cheng Chung,(unknown),Zhenlin Ju,Hai T. Tran,Edward Kim,Jonathan M. Kurie,Ja Seok Koo	57
18	Identification of Secreted Proteins that Mediate Cell-Cell Interactions in an In vitro Model of the Lung Cancer Microenvironment 2008 ·Cancer Research ·Zhong Li,Jonathon D. Roybal,Raghothama Chaerkady,Wan Zhang,Kuicheon Choi,(unknown),Hai T. Tran,Chad J. Creighton,Shaoyu Yan,Robert M. Strieter,Akhilesh Pandey,Jonathan M. Kurie	68
19	Phase I study of oral topotecan in hematological malignancies. 2003 ·PubMed ·Miloslav Beran,Susan O’Brien,Deborah A. Thomas,Hai T. Tran,Jörge E. Cortes,Francis J. Giles,Elihu H. Estey,Hagop M. Kantarjian	9
20	Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes 2002 ·Biology of Blood and Marrow Transplantation ·Jeffrey A. Russell,Hai T. Tran,Diana Quinlan,A Chaudhry,Peter Duggan,Chris Brown,Douglas A. Stewart,Joseph D. Ruether,Donald G. Morris,Stefan Glück,(unknown),Börje S. Andersson	220

About Hai T. Tran

Hai T. Tran is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 168 papers that have together received 7.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (45 papers), Cancer Genomics and Diagnostics (22 papers) and Lung Cancer Research Studies (19 papers). The work is most often cited by research in Oncology (3.5k citations), Cancer Research (1.4k citations) and Pulmonary and Respiratory Medicine (2.9k citations). Hai T. Tran has collaborated with scholars based in United States, Vietnam and China. Frequent co-authors include John V. Heymach, Roy S. Herbst, Alan Sandler, David H. Johnson, David A. Ramies, Bruce E. Johnson, Timothy Madden, Pam Klein, Vincent A. Miller and Róbert Hermann. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact